XML 61 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Share Capital (Tables)
 12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]  
Schedule of Share Capital
Share capital is composed as follows:
Issued and outstanding
Number of shares
December 31,
 20202019
Ordinary shares no par value102,334,276 99,528,435 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:
Year ended December 31,
 202020192018
Stock Option Plans
Expected term (years)
5.50-6.00
5.50-6.00
5.50-6.25
Expected volatility
54%-56%
55%-61%
52%-55%
Risk-free interest rate
0.30%-0.86%
1.73%-2.40%
2.70%-2.99%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
47%-66%
44%-62%
45%-53%
Risk-free interest rate
0.17%-1.57%
2.10%-2.51%
1.61%-2.14%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Stock Options to Purchase Ordinary Shares A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2020 and changes during the year ended on that date is presented below:
Year ended December 31, 2020
 
Number of
options
Weighted
average
exercise
price
Aggregate
intrinsic
value
Outstanding at beginning of year10,350,810 $20.40 
Granted887,188 71.87 
Exercised(1,816,851)15.72 
Forfeited and cancelled(200,821)22.98 
Outstanding at end of year9,220,326 $26.21 $1,353,785 
Exercisable options4,434,360 $16.77 $692,946 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs as of December 31, 2020 and changes during the year ended on that date is presented below:
 
Year ended December 31, 2020
 Number of
RSUs/PSUs
Weighted
average
grant date
fair value
price
Aggregate
intrinsic
value
Unvested at beginning of year1,474,395 $30.26 
Granted3,951,760 55.49 
Vested(922,299)22.09 
Forfeited and cancelled(37,705)54.88 
Unvested at end of year (1)4,466,151 $54.06 $772,822 
(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market performance which are not probable, as of December 31, 2020, in accordance with ASC 718 as follows:

December 31, 2020
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
2,703,852 $48.16 $130,218 
108,113 69.37 7,500 
17,712 84.68 1,500 
2,829,677 $139,217 
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards
The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2020, 2019 and 2018, was comprised as follows:
Year ended December 31,
 202020192018
Cost of revenues$2,221 $2,231 $1,261 
Research, development and clinical trials18,125 7,570 4,709 
Sales and marketing17,672 11,897 7,393 
General and administrative37,703 30,718 26,483 
Total share-based compensation expense$75,721 $52,416 $39,846 
Schedule of Stock Option Outstanding
The options outstanding as of December 31, 2020 are as follows:
Exercise price
Number
of options
outstanding
Weighted
average
remaining
contractual
term
Number
of options
exercisable
Weighted
average
remaining
contractual
term
$ (years) (years)
0.23 - 10.00
1,494,509 5.53947,966 5.17
10.01 - 20.00
2,874,622 5.881,872,530 5.63
20.01 - 30.00
2,144,352 6.61,192,174 6.13
30.01 - 40.00
367,127 7.57198,976 7.53
40.01 - 60.00
1,337,470 8.29193,221 8.26
60.01 - 100.00
976,609 9.1729,493 8.40
100.01 - 160.00
25,637 9.84— 0.00
 9,220,326 7.284,434,360 5.94